Jan 12, 2026 | Acquisition Cost Index (ACI), Biosimilar, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance program, Pharmacogenomics, Rx Costs, Rx prices
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Jul 11, 2025 | Comparative Effectiveness, Cost Savings, Drug costs, Evidence-based research, Formularies, High-value formulary, MedBen Rx, Rx Advertising, Rx Costs, Rx prices, Rx Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
